Drugs Xagena
Aprotinin ( Trasylol ) is associated with a 50 per cent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery.
The trial, published in the New England Journal of Medicine ( NEJM ), has shown that approximately six per cent of patients who received Aprotinin died within 30 days of surgery compared to four per cent of patients who received Tranexamic acid or Aminocaproic acid.
BART ( Blood Conservation using Antifibrinolytics in a Randomized Trial ) is one of the largest heart surgery trials ever conducted, involving more than 2,000 high-risk cardiac surgery patients.
Our study supports the use of Tranexamic acid or Aminocaproic acid over Aprotinin during high-risk heart surgery, said Paul C. Hébert, BART Co-Principal Investigator and Critical Care Physician.
BART was prematurely stopped by the trials Steering Committee in October 2007 following advice from an independent Data Safety and Monitoring Board, which detected a trend towards increased mortality in one arm of the triple-blinded study. Shortly after these preliminary results were made public, the manufacturer of Aprotinin, Bayer Pharmaceuticals, announced that the drug would be suspended from the market pending analysis of the final results of the trial.
The final results show that although Aprotinin appeared to decrease some of the consequences of massive bleeding, including the need for repeat surgery, these benefits were outweighed by the risks. The analysis showed that the increased Aprotinin-associated mortality was related to cardiac complications.
It has been estimated that between 1 and 1.25 million people undergo heart surgery every year. The use of antifibrinolytics such as Aprotinin, Tranexamic acid ( Cyklokapron ) or Aminocaproic acid ( Amicar ) has become standard practice to reduce bleeding during these surgeries.
Source: Ottawa Health Research Institute, 2008
XagenaMedicine_2008
